Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Lonza Group    LONN   CH0013841017

LONZA GROUP

(LONN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Lonza : Launches SimpliFiH Services an Integrated First-in-Human Service Package for Poorly Soluble Small Molecules

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/01/2019 | 11:00am EDT

Basel - Lonza Pharma and Biotech announced the launch of SimpliFiHTM Services, integrating its leading expertise in addressing bioavailability challenges with drug substance, solid-state characterization and drug product for first-in-human studies.

As drug discovery and development accelerate and solubility and dissolution rate challenges become more complex, new solutions are required to reduce the timeline from initial idea to a first-in-human clinical verification.

Lonza's new service package has been specifically designed for innovator companies that have solubility-challenged molecules and require drug substance and drug product services for early-stage development and first-in-human studies. Streamlined service agreement templates specific to the SimpliFiH package have also been developed to further reduce time, cost and complexity for these studies. This new offering demonstrates Lonza's continued commitment to constant innovation and adding value for its customers.

The foundation of SimpliFiH Services is the company's proprietary bioavailability enhancement technology selection methodology. This methodology encompasses databases and models based on more than 25 years' experience advancing thousands of molecules to phase I across all key enabling technologies - particle size reduction, solid dispersions and lipid-based formulations. By using this methodology, a single enabling approach for early first-in-human studies can be rapidly identified without extensive solubility screening which thereby reduces early phase clinical timelines and API requirements.

SimpliFiH Services encompasses the key drug substance and drug product components required for first-in-human studies for small molecules: drug substance development and supply, solid-state characterization/bioavailability enhancement, and phase-appropriate drug product in powder-in-capsule, powder-in-bottle, liquid-filled hard capsule or tablet format.

Basic analytical services inclusive of stability studies are included in the SimpliFiH Services package. Regulatory services for supporting, consulting on or writing IND and IMPD are available to support first-in-human requirements.

About Lonza

Lonza is an integrated solutions provider that creates value along the Healthcare Continuum. Through our Pharma Biotech & Nutrition segment and our Specialty Ingredients segment businesses, we harness science and technology to serve markets along this continuum. We focus on creating a healthy environment, promoting a healthier lifestyle and preventing illness through consumers' preventive healthcare, as well as improving patient healthcare by supporting our customers to deliver innovative medicines that help treat or even cure severe diseases. Patients and consumers benefit from our ability to transfer our pharma know-how to the healthcare, hygiene and fast-moving consumer goods environment and to the preservation and protection of the world where we live.

Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 100 sites and offices and approximately 15,500 full-time employees worldwide at the end of 2018. The company generated sales of CHF 5.5 billion in 2018 with a CORE EBITDA of CHF 1.5 billion.

Contact:

Dirk Oehlers

Tel: +41 61 316 8540

Email: dirk.oehlers@lonza.com

Additional Information and Disclaimer

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited ('SGX-ST'). Lonza Group Ltd is not subject to the SGX-ST's continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.

(C) 2019 Electronic News Publishing, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on LONZA GROUP
06/11LONZA : Engine Equipment Portfolio Launched for Small Molecule Formulation and D..
AQ
06/06LONZA : to Host New Webinar Titled 'Know Your Enemy Mycoplasma Contamination in ..
AQ
06/03Carve-out of Lonza Specialty Ingredients will help segment to become a global..
TE
05/21Global chemical firms urged to source responsibly after lethal China blast - ..
RE
05/18LONZA : Defense Logistics Agency Energy Aerospace Energy awarded $8m contract fo..
AQ
05/14LONZA : Chiasma and Lonza Announce Progression of Oral Octreotide Capsules Devel..
AQ
05/08LONZA : Showcases New SYNETH Product Range of Polyglycerol Esters for Perfect Ba..
AQ
05/07LONZA : Showcases New SYNETH™ Product Range of Polyglycerol Esters for Per..
PU
05/07LONZA : Highlights H2OBioEV™ Bioactive Functional for Skin Rejuvenation at..
PU
05/07LONZA : Previews its Newest Clean Label Innovation - Vcaps plus White Opal, a Ti..
AQ
More news
Financials (CHF)
Sales 2019 5 921 M
EBIT 2019 1 170 M
Net income 2019 808 M
Debt 2019 2 924 M
Yield 2019 0,90%
P/E ratio 2019 28,89
P/E ratio 2020 26,00
EV / Sales 2019 4,53x
EV / Sales 2020 4,18x
Capitalization 23 927 M
Chart LONZA GROUP
Duration : Period :
Lonza Group Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LONZA GROUP
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Average target price 335  CHF
Spread / Average Target 4,2%
EPS Revisions
Managers
NameTitle
Richard Ridinger Chief Executive Officer
Albert M. Baehny Chairman
Rodolfo Savitzky Chief Financial Officer
Patrick Aebischer Vice Chairman
Margot A. Scheltema Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
LONZA GROUP29.21%24 012
IQVIA HOLDINGS INC21.63%26 223
CELLTRION, INC.--.--%20 953
INCYTE CORPORATION22.20%17 061
EXACT SCIENCES CORPORATION73.98%13 037
SEATTLE GENETICS, INC.20.90%10 947